EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacogenomics (London)

• Publication date

  2013-11-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.13.177PMID 24192124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor inhibition in lung cancer: status 2012.

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer

  2013cited by this paper
• Novel therapeutic targets in non-small cell lung cancer.

  2013cited by this paper
• Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells

  2013cited by this paper
• Role of genetic polymorphisms in the angiogenesis pathway and non-small-cell lung cancer tumor behavior: Implications in risk assessment and clinical outcome

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

  2013cited by this paper
• Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy

  2013cited by this paper
• Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

  2013cited by this paper
• Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies.

  2012cited by this paper
• Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.

  2012cited by this paper
• Cetuximab in non-small-cell lung cancer.

  2012cited by this paper
• Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients

  2012cited by this paper
• Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.

  2012cited by this paper
• Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

  2012cited by this paper
• Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study

  2012cited by this paper
• Feedback within the Inter-Cellular Communication and Tumorigenesis in Carcinomas

  2012cited by this paper
• Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma

  2012cited by this paper
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• Personalizing medicine – strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal

  2012cited by this paper
• Personalizing medicine: strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal.

  2012cited by this paper
• First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

  2012cited by this paper
• Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

  2012cited by this paper
• Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

  2012cited by this paper
• Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

  2012cited by this paper
• Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices

  2012cited by this paper
• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

  2012cited by this paper
• Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

  2011cited by this paper
• Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy

  2011cited by this paper
• Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.

  2011cited by this paper
• Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

  2011cited by this paper
• Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

  2011cited by this paper
• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

  2011cited by this paper
• Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.

  2011cited by this paper
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  2010cited by this paper
• Clinical Features of Bronchioloalveolar Carcinoma with New Histologic and Staging Definitions

  2010cited by this paper
• Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

  2010cited by this paper
• The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.

  2010cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• The association of telomere length and genetic variation in telomere biology genes a

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients.

  2009cited by this paper
• The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung.

  2009cited by this paper
• Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

  2009cited by this paper
• Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

  2009cited by this paper
• Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

  2009cited by this paper
• EML4-ALK: honing in on a new target in non-small-cell lung cancer.

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Are RAS mutations predictive markers of resistance to standard chemotherapy?

  2009cited by this paper
• Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• The role of the Angiopoietins in vascular morphogenesis

  2009cited by this paper
• Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer

  2008cited by this paper
• Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

  2008cited by this paper
• Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer

  2008cited by this paper
• Targeting p53 to mitochondria for cancer therapy

  2008cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  2008cited by this paper
• Involvement of nuclear factor‐kappa B in bcl‐xL‐induced interleukin 8 expression in glioblastoma

  2008cited by this paper
• Unlocking the biological clues of lung cancer.

  2008cited by this paper
• KRAS mutations predict response to EGFR inhibitors.

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition

  2008cited by this paper
• Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

  2008cited by this paper
• AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

  2007cited by this paper
• Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Targeting the tumor microenvironment.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

  2007cited by this paper
• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper

• Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases

  2024cites this paper
• Inhibin βA is an independent prognostic factor that promotes invasion via Hippo signaling in non-small cell lung cancer

  2021cites this paper
• Nuances to precision dosing strategies of targeted cancer medicines

  2020cites this paper
• Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.

  2020cites this paper
• Application of malignant pleural effusion cell blocks in the diagnosis and personalized treatment of advanced non-small cell lung carcinoma

  2019cites this paper
• Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro

  2019cites this paper
• Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling

  2019cites this paper
• Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma

  2018cites this paper
• Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers

  2018cites this paper
• Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs

  2018cites this paper
• Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis

  2017cites this paper
• Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade

  2017cites this paper
• Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.

  2017cites this paper
• Learning from biomedical linked data to suggest valid pharmacogenes

  2017cites this paper
• Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.

  2016cites this paper
• A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.

  2016cites this paper
• Tumor exosomes: cellular postmen of cancer diagnosis and personalized therapy.

  2016cites this paper
• ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance

  2016cites this paper
• TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?

  2016cites this paper
• Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer

  2015cites this paper
• Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.

  2015cites this paper
• Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide

  2015cites this paper
• Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma.

  2015cites this paper
• The future of patient-derived tumor xenografts in cancer treatment.

  2015cites this paper
• Thyroid Hormone, Hormone Analogs, and Angiogenesis.

  2015cites this paper
• Therapeutic Potential of Targeting PAK Signaling.

  2015cites this paper
• Bringing Next-Generation Sequencing Oncology Tests into the DiagnosticSetting

  2015cites this paper
• Nivolumab for advanced squamous cell lung cancer: what are the next steps?

  2015cites this paper
• Immunotherapy for lung cancer: for whom the bell tolls?

  2015cites this paper
• BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy

  2014cites this paper
• Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

  2014cites this paper
• Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations

  2014cites this paper
• Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer

  2014cites this paper
• IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach

  2014cites this paper
• Understanding lung cancer molecular subtypes

  2014cites this paper
• Multiple Choice Questions with explanations

  2012cites this paper